Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 14/20 | 0.54 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.38 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.38 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12386173 | 0.91 | MET (0.49) | METRPS6KA3SMN1; SMN2POLBMAPK1 | |
| SCHEMBL1415006 | 0.89 | MET (0.58) | METRPS6KA3SMN1; SMN2POLBMAPK1 | |
| SCHEMBL1411866 | 0.87 | MET (0.58) | METRPS6KA3SMN1; SMN2POLBMAPK1 | |
| SCHEMBL1415055 | 0.87 | MET (0.66) | METRPS6KA3SMN1; SMN2POLBMAPK1 | |
| SCHEMBL29931188 | 0.87 | MET (0.66) | METRPS6KA3SMN1; SMN2POLBMAPK1 | |
| SCHEMBL1415098 | 0.86 | MET (0.55) | METRPS6KA3SMN1; SMN2POLBMAPK1 | |
| SCHEMBL1414940 | 0.85 | MET (0.54) | METRPS6KA3SMN1; SMN2POLBMAPK1 | |
| SCHEMBL1414931 | 0.84 | MET (0.60) | METRPS6KA3SMN1; SMN2POLBMAPK1 | |
| SCHEMBL1415004 | 0.83 | MET (0.52) | METRPS6KA3SMN1; SMN2POLBMAPK1 | |
| SCHEMBL13685516 | 0.80 | MET (0.53) | METRPS6KA3SMN1; SMN2POLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551989-B2 | Substituted 4-(indazolyl)-1,4-dihydropyridines and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-8551989-B2 | Substituted 4-(indazolyl)-1,4-dihydropyridines and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| EP-2294062-B1 | SUBSTITUTED 4- (INDAZOLYL) -1,4-DIHYDROPYRIDINES AND METHODS OF USE THEREOF | BAYER IP GMBH (DE) | 2013-08-21 | — | — | EP | disclosed |
| EP-2294062-B1 | SUBSTITUTED 4- (INDAZOLYL) -1,4-DIHYDROPYRIDINES AND METHODS OF USE THEREOF | BAYER IP GMBH (DE) | 2013-08-21 | — | — | EP | disclosed |
| US-20110207731-A1 | SUBSTITUTED 4-(INDAZOLYL)-1,4-DIHYDROPYRIDINES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-25 | — | — | US | disclosed |
| US-20110207731-A1 | SUBSTITUTED 4-(INDAZOLYL)-1,4-DIHYDROPYRIDINES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-25 | — | — | US | disclosed |
| EP-2294062-A1 | SUBSTITUTED 4- (INDAZOLYL) -1,4-DIHYDROPYRIDINES AND METHODS OF USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-03-16 | — | — | EP | disclosed |
| WO-2009149837-A1 | SUBSTITUTED 4- (INDAZOLYL) -1,4-DIHYDROPYRIDINES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009149837-A1 | SUBSTITUTED 4- (INDAZOLYL) -1,4-DIHYDROPYRIDINES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207731-A1 | SUBSTITUTED 4-(INDAZOLYL)-1,4-DIHYDROPYRIDINES AND METHODS OF USE THEREOF | MET, ERBB4, RET | MET 1/4885RPS6KA3 752/4885SMN1; SMN2 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.